LT4214240T - Anti-ccr8 antikūnai - Google Patents
Anti-ccr8 antikūnaiInfo
- Publication number
- LT4214240T LT4214240T LTEPPCT/US2022/074214T LTUS2022074214T LT4214240T LT 4214240 T LT4214240 T LT 4214240T LT US2022074214 T LTUS2022074214 T LT US2022074214T LT 4214240 T LT4214240 T LT 4214240T
- Authority
- LT
- Lithuania
- Prior art keywords
- ccr8 antibodies
- ccr8
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163226118P | 2021-07-27 | 2021-07-27 | |
PCT/US2022/074214 WO2023010054A1 (en) | 2021-07-27 | 2022-07-27 | Anti-ccr8 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
LT4214240T true LT4214240T (lt) | 2024-11-25 |
Family
ID=82898810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/US2022/074214T LT4214240T (lt) | 2021-07-27 | 2022-07-27 | Anti-ccr8 antikūnai |
Country Status (25)
Country | Link |
---|---|
US (1) | US11639393B2 (lt) |
EP (2) | EP4491635A2 (lt) |
JP (1) | JP7638935B2 (lt) |
KR (1) | KR20240067052A (lt) |
CN (1) | CN117425677A (lt) |
AR (1) | AR126578A1 (lt) |
AU (1) | AU2022317803A1 (lt) |
BR (1) | BR112023024837A2 (lt) |
CA (1) | CA3220121A1 (lt) |
CO (1) | CO2023015915A2 (lt) |
DK (1) | DK4214240T3 (lt) |
ES (1) | ES2995868T3 (lt) |
FI (1) | FI4214240T3 (lt) |
HR (1) | HRP20241561T1 (lt) |
HU (1) | HUE069018T2 (lt) |
IL (1) | IL307533A (lt) |
LT (1) | LT4214240T (lt) |
MX (1) | MX2023014154A (lt) |
PL (1) | PL4214240T3 (lt) |
PT (1) | PT4214240T (lt) |
RS (1) | RS66234B1 (lt) |
SI (1) | SI4214240T1 (lt) |
SM (1) | SMT202400483T1 (lt) |
TW (1) | TW202321304A (lt) |
WO (1) | WO2023010054A1 (lt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
WO2024165470A1 (en) | 2023-02-06 | 2024-08-15 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
WO2017198631A1 (en) | 2016-05-16 | 2017-11-23 | Istituto Nazionale Di Genetica Molecolare - Ingm | Markers selectively deregulated in tumor-infiltrating regulatory t cells |
WO2018112033A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs |
CA3057274C (en) | 2017-03-29 | 2023-10-10 | Shionogi & Co., Ltd. | Pharmaceutical composition for cancer treatment |
CA3124332A1 (en) * | 2018-12-27 | 2020-07-02 | Shionogi & Co., Ltd. | Novel anti-ccr8 antibody |
MX2022008341A (es) | 2020-01-06 | 2022-08-10 | Vaccinex Inc | Anticuerpos anti-ccr8 y usos de estos. |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
EP4114862A4 (en) | 2020-03-05 | 2024-07-03 | Memorial Sloan Kettering Cancer Center | Anti-ccr8 agents |
JP2023519254A (ja) | 2020-03-23 | 2023-05-10 | ブリストル-マイヤーズ スクイブ カンパニー | がんを処置するための抗ccr8抗体 |
TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
JP7610302B2 (ja) | 2020-08-28 | 2025-01-08 | ハーバー・バイオメド・(シャンハイ)・カンパニー・リミテッド | Ccr8抗体及びその用途 |
WO2022081718A1 (en) | 2020-10-14 | 2022-04-21 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
KR20230088426A (ko) | 2020-10-16 | 2023-06-19 | 라노바 메디신즈 리미티드 컴파니 | 항-ccr8 단클론성 항체 및 그것의 용도 |
WO2022136647A1 (en) | 2020-12-24 | 2022-06-30 | Oncurious Nv | Human ccr8 binders |
US20240052044A1 (en) | 2020-12-24 | 2024-02-15 | Vib Vzw | Non-blocking human ccr8 binders |
-
2022
- 2022-07-27 BR BR112023024837A patent/BR112023024837A2/pt unknown
- 2022-07-27 DK DK22754752.8T patent/DK4214240T3/da active
- 2022-07-27 KR KR1020237041895A patent/KR20240067052A/ko active Pending
- 2022-07-27 SM SM20240483T patent/SMT202400483T1/it unknown
- 2022-07-27 LT LTEPPCT/US2022/074214T patent/LT4214240T/lt unknown
- 2022-07-27 IL IL307533A patent/IL307533A/en unknown
- 2022-07-27 TW TW111128155A patent/TW202321304A/zh unknown
- 2022-07-27 PT PT227547528T patent/PT4214240T/pt unknown
- 2022-07-27 HU HUE22754752A patent/HUE069018T2/hu unknown
- 2022-07-27 EP EP24198142.2A patent/EP4491635A2/en active Pending
- 2022-07-27 EP EP22754752.8A patent/EP4214240B1/en active Active
- 2022-07-27 JP JP2022119632A patent/JP7638935B2/ja active Active
- 2022-07-27 RS RS20241306A patent/RS66234B1/sr unknown
- 2022-07-27 HR HRP20241561TT patent/HRP20241561T1/hr unknown
- 2022-07-27 CA CA3220121A patent/CA3220121A1/en active Pending
- 2022-07-27 MX MX2023014154A patent/MX2023014154A/es unknown
- 2022-07-27 US US17/815,505 patent/US11639393B2/en active Active
- 2022-07-27 FI FIEP22754752.8T patent/FI4214240T3/fi active
- 2022-07-27 PL PL22754752.8T patent/PL4214240T3/pl unknown
- 2022-07-27 CN CN202280040102.9A patent/CN117425677A/zh active Pending
- 2022-07-27 WO PCT/US2022/074214 patent/WO2023010054A1/en active Application Filing
- 2022-07-27 AR ARP220101985A patent/AR126578A1/es unknown
- 2022-07-27 ES ES22754752T patent/ES2995868T3/es active Active
- 2022-07-27 AU AU2022317803A patent/AU2022317803A1/en active Pending
- 2022-07-27 SI SI202230078T patent/SI4214240T1/sl unknown
-
2023
- 2023-11-22 CO CONC2023/0015915A patent/CO2023015915A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
RS66234B1 (sr) | 2024-12-31 |
BR112023024837A2 (pt) | 2024-02-20 |
SMT202400483T1 (it) | 2025-01-14 |
PL4214240T3 (pl) | 2025-01-07 |
JP2023018678A (ja) | 2023-02-08 |
AU2022317803A1 (en) | 2023-10-26 |
EP4491635A2 (en) | 2025-01-15 |
CO2023015915A2 (es) | 2023-12-11 |
MX2023014154A (es) | 2024-05-14 |
SI4214240T1 (sl) | 2025-02-28 |
US20230048553A1 (en) | 2023-02-16 |
TW202321304A (zh) | 2023-06-01 |
HUE069018T2 (hu) | 2025-02-28 |
JP7638935B2 (ja) | 2025-03-04 |
WO2023010054A1 (en) | 2023-02-02 |
EP4214240A1 (en) | 2023-07-26 |
DK4214240T3 (da) | 2024-11-18 |
PT4214240T (pt) | 2024-11-25 |
FI4214240T3 (fi) | 2024-11-14 |
KR20240067052A (ko) | 2024-05-16 |
IL307533A (en) | 2023-12-01 |
CN117425677A (zh) | 2024-01-19 |
CA3220121A1 (en) | 2023-02-02 |
HRP20241561T1 (hr) | 2025-02-14 |
ES2995868T3 (en) | 2025-02-11 |
US11639393B2 (en) | 2023-05-02 |
EP4214240B1 (en) | 2024-10-09 |
AR126578A1 (es) | 2023-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT202300397T1 (it) | Anticorpi contro sars-cov-2 | |
IL289112A (en) | Antibodies against tigit | |
IL291068A (en) | Anti-cd73 antibodies | |
IL284584A (en) | Anti-tigit antibodies | |
IL308741A (en) | Anti-SIRP-alpha antibodies | |
GB202105110D0 (en) | Anti-CD73 antibodies | |
GB201905150D0 (en) | Ant-ige antibodies | |
GB202014851D0 (en) | SARS-COV-2 antibodies | |
LT4214240T (lt) | Anti-ccr8 antikūnai | |
ZA202209699B (en) | Novel antibodies | |
GB201900732D0 (en) | Antibodies | |
GB201917480D0 (en) | Antibodies | |
IL308782A (en) | Antibodies | |
IL308100A (en) | Antibodies | |
GB202111905D0 (en) | Antibodies | |
IL300142A (en) | Anti-IL13Ralpha2 antibodies | |
IL299767A (en) | Antibodies against Alpha-4-Beta-7 | |
IL289160A (en) | Anti-angpt2 antibodies | |
GB202015115D0 (en) | ZIP12 Antibody | |
GB2598698B (en) | Affinity-maturated anti-ASICIa antibodies | |
GB202208773D0 (en) | Anti-SARS2-S antibodies | |
IL307175A (en) | IL-38 specific antibodies | |
GB202116709D0 (en) | Antibodies | |
GB202115824D0 (en) | Antibodies | |
GB202112297D0 (en) | Antibodies |